Skip to main content
. 2019 Aug 16;21(1):7–17. doi: 10.1021/acs.biomac.9b01053

Table 2. Cryoprotective Outcomes Using Polyampholytes.

Structurea [Polymer] (wt %) Cell type Cell viabilityb Freezing ratec Other CPAsd Ref
2 7 L929 ∼95% Slow freezing 1 °C·min–1 None (60)
3 15 L929 ∼90% Slow freezing NCe None (62)
4 10 L929 ∼95% Slow freezing NCe None (63)
5 15   <10%      
6 15   ∼70%      
7 2 RBC ∼65% Vitrification direct into LN2 350 mg·mL–1 HES, 30 mg·mL–1 mannitol and 6.5 mg·mL–1 NaCl (65)
8 12 L929 ∼90% Slow freezing NCe None (87)
2 10 MSC Monolayer ∼80% Slow freezing 4.9 °C·min–1 6.5 M EGf, 0.5 M sucrose (25)
3 10 L929 ∼60% Slow freezing NCe None (61)
9 10   ∼70%      
4 10   96%      
10 10 3T3 70% Slow freezing 1 °C·min–1 2% DMSO (83)
11 10   90%      
2 20 PN Pig embryo Higher development rate Vitrification direct into LN2 30% EGf, 0.5 M sucrose (91)
2 10 Chondrocyte sheet All sheets recovered Vitrification direct into LN2 20% DMSO, 20% EGf, 0.5 M sucrose (89)
2 10 Mouse oocyte 95% Survival after fertilization Vitrification direct into LN2 20% EGf, 0.5 M sucrose (90)
2 7.5 Human mesenchymal stem cells 90% Viability after 24 months Slow freezing NCe None (93)
1 2 A549 Suspension 50% Slow freezing 1 °C·min–1 5% DMSO (24)
1 4 A549 Monolayer 90% Slow freezing 1 °C·min–1 5% DMSO  
a

Representative structure reproduced from reference.

b

Viability of the cells as reported.

c

If included in original ref.

d

Any other materials added to the cryopreservation solution.

e

Not controlled, final storage temperature −80 °C.

f

EG is ethylene glycol.